The Maintenance Treatment of UFT in Advanced Gastric Cancer
The purpose of this study is to evaluate the efficacy and tolerability of the maintenance treatment of tegafur-uracil (UFT) after the standard first-line chemotherapy in advanced gastric cancer.
Gastric Cancer
DRUG: UFT
Progression Free Survival (PFS), PFS is calculated from the start of treatment to disease progression or death, six weeks
Overall Survival (OS), OS is calculated from the start to treatment to the death, six weeks|Number of Participants with Adverse Events, six weeks
The purpose of this study is to evaluate the efficacy and tolerability of the maintenance treatment of tegafur-uracil (UFT) after the standard first-line chemotherapy in advanced gastric cancer.